Alliance Pharma in better health after flagship products trigger sales growth

July 14, 2015
By

Sales have started growing again at Chippenham-based speciality pharmaceutical firm Alliance Pharma, after a slight fall last year, its bosses said this week.

The firm, which acquires and develops niche drugs, said in a trading update to shareholders that sales for the half year to June 30 were likely to reach £22.8m – up 6.1% on the same period last year.

Its growth products continued to deliver, with dry skin treatment Hydromol generating sales of £3.3m in the period – 10% higher than in the same period last year and despite a reduction in rebate it receives under the Pharmaceutical Price Regulation Scheme.

MacuShield, the eye care product acquired for £5.5m in February, was performing in line with expectations, while production of its bladder cancer treatment ImmuCyst would resume in the second half for the first time since it was halted in mid-2012. The treatment had peak annual sales of more than £4m before output was suspended.

The firm was continuing to explore a number of acquisition opportunities, it said. In March, it reported sales in the year to December 31 had fallen by 4% to £43.5m, with pre-tax profits coming in 10% lower at £10.8m.

Interim results for the six months ended June 30 are scheduled to be released on September 9.

 

Comments are closed.

ADVERTISE HERE

Reach tens of thousands of senior business people across the Bath area for just £75 a month. Email info@bath-business.net for more information.